Meds & supplements › Cenobamate
Medicine
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
The following serious adverse reactions are described in more detail in the Warnings and Precautions section of the labeling:
XCOPRI is contraindicated in patients with:
Store XCOPRI tablets at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) (See USP Controlled Room Temperature).
XCOPRI tablets are supplied in the following configurations:
Bottles; 30 count
Titration Blister Packs; 14-Day
Titration Blister Packs; 28-Day
Maintenance Blister Packs; 28-Day
sofidex [Internet]. Daloreum; c2026. Cenobamate; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/cenobamate
sofidex. (2026, August 2). Cenobamate. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/cenobamate
Cenobamate. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/cenobamate
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.